## Pathway Pearls



## Optimizing HF/COPD Medication

Pharmacists/Nurse Practitioners share collaboration strategies and discuss best practice

## Learning Objectives

- Review recommendations
- Identify resources providing Best Practice Recommendations
- Discuss approach to optimizing HF/ COPD medications
- Share site experiences with medication optimization
- Identify 2 Pathway Pearls to assist implementation


## Outline

- Recommendations
- Optimizing HF / COPD Medications
(Mike Johnson, Pharmacist, Medicine Hat Hospital)
- Group Discussion:
- How it works in your setting
- Challenges / solutions
- Wrap Up


# GOLD 2018 Summary Report: Global Strategy for the Diagnosis, Management and Prevention of COPD 

Discharge Criteria: The introduction of care bundles should include education, optimization of medication, supervision and correction of inhaler technique, assessment and optimal management of comorbidities, early rehabilitation, telemonitoring and continued patient contact are all been investigated to address these issues (2018, p. 107)

## 2017 Comprehensive Update of the Canadian

 Cardiovascular Society Guidelines for the Management of Heart FailurePrinciples underpinning the pharmacological management of HFpEF include:
(1) identification and treatment of underlying etiological factors implicated in the development of HFpEF;
(2) identification and treatment of comorbid conditions that might exacerbate the HF syndrome;
(3) control of symptoms; and
(4) realization of clinically meaningful cardiovascular


Pathway Pearls: Optimizing HF/COPD Medication

## Presentation

## Mike Johnson

- Introduction

Pharmacist
Medicine Hat Regional Hospital

## Pathway Pearls: Optimizing HF/COPD Medication

## 



| Alberta Health Services Maintenance Inhal | erapy | Affix patient label within this box |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Drug | Brand | Available Stren | gths | Delivery <br> Device | Ordering Dose |
| Long Acting Muscarinic Antagonists (LAMA) |  |  |  |  |  |
| tiotropium | Spiriva HandiHaler | $18 \mathrm{mcg} /$ dose |  | DPI | 1 puff daily |
| tiotropium | Spiriva Respimat | $2.5 \mathrm{mcg} /$ dose |  | SMI | 2 puffs daily |
| aclidinium | Tudorza Genuair | $400 \mathrm{mcg} / \mathrm{dos}$ |  | DPI | 1 puff BID |
| glycopyrronium | Seebri Breezhaler | $50 \mathrm{mcg} / \mathrm{dose}$ |  | DPI | 1 puff daily |
| Long-Acting Beta-Agonists (LABA) |  |  |  |  |  |
| salmeterol | Serevent Diskus | $50 \mathrm{mcg} /$ dose |  | DPI | 1 puff BID |
| formoterol | Oxeze Turbuhaler | $12 \mathrm{mcg} /$ dose |  | DPI | 1 puff BID |
| indacaterol | Onbrez Breezhaler | $75 \mathrm{mcg} / \mathrm{dose}$ |  | DPI | 1 puff daily |
| Combination LAMA/LABA (Restricted use sane cortaria 2 or 31 |  |  |  |  |  |
| Heart Failure |  |  |  |  |  |
| CCS 2014 Evidence Based Heart Failure Drugs/Dosest for Patients with Systolic LV Dysfunction |  |  |  |  |  |
| Drug | Start Dose (orally |  | Targe | Dose (orally |  |
| ACE inhibitors |  |  |  |  |  |
| capTOPRIL | 6.25 to 12.5 mg |  | 25 to | 0 mg TID |  |
| enalapril maleate | 1.25 to 2.5 mg B |  | 10 mg |  |  |
| lisinopril | 2.5 to 5 mg Daily |  | 20 to | 5 mg Daily |  |
| perindopril | 2 to 4 mg Daily |  | 4 to 8 | mg Daily |  |
| ramipril | 1.25 to 2.5 mg B |  | 5 mg |  |  |
| trandolapril | 1 to 2 mg Daily |  | 4 mg |  |  |
| Beta-blockers |  |  |  |  |  |
| bisoPROLol | 1.25 mg Daily |  | 10 mg | Daily |  |
| carVEDilol | 3.125 mg BID |  | 25 mg | BIDt† |  |
| ARBs |  |  |  |  |  |
| candesartan | 4 mg Daily |  | 32 mg | Daily |  |
| valsartan | 40 mg BID |  | 160 m | BID |  |

## Pathway Pearls: Optimizing HF/COPD Medication

## Documentation - Optimizing HF \& COPD Medication Therapy

## Transition to Community Care

| COPD Admission to Discharge Checklist     <br> Admission Date (yyy-Mon-dd) Time (hh:mm)    <br> Activity Completed    <br> Patient Education Yes No N/A  <br> Initial     <br> 1. Provide 'Patient Education Resource Package' - Review with patient/caregiver     <br> a) COPD Medications     <br> b) Inhaler Technique     <br> c) COPD: Learning to Breathe Easier     <br> d) COPD: Avoiding Your Triggers     <br> e) Pneumococcal / Influenza Vaccines     <br> f) Tobacco use; assess, provide brief intervention, and tobacco cessation     <br> support resources.     <br> Patient Demonstration     <br> 2. Patient demonstrates adequate inhaler technique     <br> Prior to Discharge Review results, where relevant, and ensure appropriate follow-up     <br> 3. Early mobilization (done within 48 hours by any discipline)     <br> A. Review and optimize respiratory medication     |
| :--- |

## Admission to Discharge Checklist

Participants are encouraged to participate in session talks.

If you would like to email your question, please send to:

## hfpathway@ahs.ca

